Paying users zone. Data is covered by .

  • Get to Allergan PLC for $13.99, or

  • get to whole website for at least 3 months from $49.99.

 

$13.99


Ratios (Summary)

Allergan PLC, long-term (investment) activity ratios

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net fixed asset turnover
Total asset turnover
Equity turnover

Source: Based on data from Allergan PLC Annual Reports

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Allergan PLC's net fixed asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Allergan PLC's total asset turnover improved from 2015 to 2016 and from 2016 to 2017.
Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Allergan PLC's equity turnover deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.

Top


Net Fixed Asset Turnover

Allergan PLC, net fixed asset turnover calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Net revenues
Property, plant and equipment, net
Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Net Fixed Asset Turnover, Sector
Pharmaceuticals & Biotechnology
Net Fixed Asset Turnover, Industry
Health Care

Source: Based on data from Allergan PLC Annual Reports

2017 Calculations

1 Net fixed asset turnover = Net revenues ÷ Property, plant and equipment, net
= ÷ =

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Allergan PLC's net fixed asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Total Asset Turnover

Allergan PLC, total asset turnover calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Net revenues
Total assets
Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Total Asset Turnover, Sector
Pharmaceuticals & Biotechnology
Total Asset Turnover, Industry
Health Care

Source: Based on data from Allergan PLC Annual Reports

2017 Calculations

1 Total asset turnover = Net revenues ÷ Total assets
= ÷ =

Ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Allergan PLC's total asset turnover improved from 2015 to 2016 and from 2016 to 2017.

Top


Equity Turnover

Allergan PLC, equity turnover calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Net revenues
Shareholders' equity
Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Equity Turnover, Sector
Pharmaceuticals & Biotechnology
Equity Turnover, Industry
Health Care

Source: Based on data from Allergan PLC Annual Reports

2017 Calculations

1 Equity turnover = Net revenues ÷ Shareholders' equity
= ÷ =

Ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Allergan PLC's equity turnover deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.

Top